Cialis Safety Signals and FDA Actions: What the Evidence Shows

The direct answer

Tadalafil's safety record since 2003 shows no recall and no boxed warning, but it does show a real pattern of postmarketing label revisions driven by rare, serious events: sudden vision loss possibly linked to NAION, sudden sensorineural hearing loss, and priapism. The one non-negotiable safety rule is the nitrate contraindication, because combining tadalafil with any nitrate can cause dangerous hypotension. Cardiovascular event risk and a possible melanoma association remain areas of ongoing observational research rather than settled, label-confirmed hazards, and readers should not equate "an association has been studied" with "the FDA has concluded this drug causes it."

What tadalafil is and how it works

Tadalafil inhibits phosphodiesterase type 5 (PDE5), an enzyme that breaks down cyclic GMP in smooth muscle. During sexual stimulation, nitric oxide release triggers cGMP production in penile tissue; blocking its breakdown sustains smooth muscle relaxation and blood flow. PDE5 is not limited to penile tissue. It is also present in pulmonary vascular smooth muscle, which is why tadalafil is separately approved (as Adcirca) for pulmonary arterial hypertension, and clinical reviews of PDE5 inhibitors in that setting describe the same underlying vasodilatory mechanism operating in the pulmonary circulation (Rich, 2006).

A key pharmacologic feature is tadalafil's long half-life, commonly cited as roughly 17.5 hours, considerably longer than sildenafil's. This is the basis for once-daily dosing options and for the drug's informal reputation for a longer window of effect. It is also directly relevant to the nitrate warning below, because a longer half-life means a longer required nitrate-free interval after the last dose. The precise pharmacokinetic figures and any drug-interaction magnitude numbers cited elsewhere for tadalafil should be checked against the current FDA-approved label rather than assumed from secondary sources, since the specific citations available for this review could not be independently confirmed as matching the exact claims made.

Regulatory timeline: what the FDA has actually done

The core, verifiable regulatory facts are:

• 2003: FDA approval for erectile dysfunction under NDA 021368.
• 2005: FDA-requested class-wide label revision for PDE5 inhibitors adding a precaution about non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden one-eye vision loss.
• 2007: A second class-wide label revision added sudden sensorineural hearing loss to the warnings and precautions section for Cialis, Levitra, and Viagra, based on postmarketing reports across the drug class.
• 2011: FDA approval of tadalafil 5 mg daily for BPH and for BPH with concurrent erectile dysfunction, per the FDA-approved prescribing information per the FDA-approved prescribing information.
• 2018: Generic tadalafil entered the U.S. market after patent expiration.

No market withdrawal, Risk Evaluation and Mitigation Strategy (REMS), or boxed warning has been applied to tadalafil based on the label version available for this review. That status is worth reconfirming periodically, since label status is the kind of fact that can change and should be dated to whenever a reader is relying on it.

The nitrate contraindication: the one rule that is not negotiable

This is the highest-confidence, most consequential safety fact on this page. Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and recreational nitrites ("poppers") are absolutely contraindicated with tadalafil, per the FDA label. Both drug classes raise cGMP-mediated vasodilation through overlapping pathways, and together they can produce severe, symptomatic, and potentially fatal hypotension.

Because tadalafil's half-life is substantially longer than shorter-acting PDE5 inhibitors, clinicians generally recommend a longer nitrate-free interval after a tadalafil dose than after sildenafil or vardenafil. Cardiology guidance on sexual activity and cardiovascular disease has addressed this timing question directly; the exact recommended interval should be confirmed against the current version of that guideline rather than repeated from memory, since guideline documents are periodically revised. The clinical stakes are highest in an emergency department, where a chest pain patient's recent PDE5 inhibitor use must be identified before nitroglycerin is given.

Cardiovascular safety: established finding versus open question

What is reasonably well established: large pooled analyses of clinical trial data on tadalafil have not shown an increased rate of myocardial infarction compared with placebo, and professional cardiology consensus statements have generally classified PDE5 inhibitors as usable in men at low cardiovascular risk. What is not established with the same confidence, at least from the sources available for this review, is a precise quantified risk figure (an exact patient-year incidence rate, for example) that can be cited without checking the original trial-level publication. Readers and editors should treat any specific numeric risk estimate for tadalafil and MI as needing verification against the primary trial or meta-analysis before it is published as fact.

A more mechanistically clear and lower-controversy finding is that tadalafil produces a modest reduction in systolic blood pressure in clinical trials, and that this effect can be additive with alpha-blockers (used for BPH) and with other antihypertensive drugs. The FDA label instructs that patients should be hemodynamically stable on alpha-blocker therapy before starting tadalafil, and recommends starting at the lowest appropriate dose in that situation.

Vision changes: the NAION signal

In 2005 the FDA requested a class-wide warning for PDE5 inhibitors covering non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden, painless vision loss in one eye from reduced blood flow to the optic nerve. NAION is rare in the general population, and its risk factors (hypertension, diabetes, high cholesterol, smoking) overlap heavily with the risk factors for erectile dysfunction itself, which makes it genuinely difficult to separate a drug effect from a shared-risk-factor effect using observational data alone. Case-crossover studies have reported statistically significant associations in some analyses, while larger cohort studies have been less consistent. The FDA has not reversed or strengthened this warning beyond the original class-wide language, and the current label advises stopping the drug and seeking immediate medical attention if sudden vision loss occurs in one or both eyes, with added caution for men who have already had NAION in one eye.

Color vision disturbance (a blue tinge, sometimes called cyanopsia) is more strongly associated with sildenafil, which cross-reacts with PDE6 in retinal photoreceptors more than tadalafil does; tadalafil's greater selectivity for PDE5 over PDE6 is the pharmacologic reason this particular side effect is less commonly reported with tadalafil specifically.

Hearing loss: the 2007 class-wide update

The FDA's October 2007 label revision for all three PDE5 inhibitors added sudden sensorineural hearing loss, sometimes with accompanying tinnitus or dizziness, to warnings and precautions, based on a small number of postmarketing reports across the drug class. The FDA's own position, as reflected in that communication, is that a causal relationship has not been established but could not be ruled out, and that patients should stop the drug and seek prompt medical attention for sudden hearing changes. A proposed mechanism involves PDE5-mediated vasodilation affecting cochlear microvasculature, but this remains a plausible hypothesis rather than a confirmed mechanism. The absolute incidence, based on spontaneous adverse event reporting, appears very low, though spontaneous reporting systems cannot establish a true population rate.

Priapism

An erection lasting four hours or longer (priapism) is a recognized, rare, class-level adverse event for PDE5 inhibitors, including tadalafil, and is listed on the label as requiring emergency treatment because delayed treatment beyond roughly four to six hours can cause permanent damage to erectile tissue. Risk is higher in men with sickle cell disease, multiple myeloma, leukemia, or anatomical penile conditions such as Peyronie's disease, and the label instructs clinicians to counsel these patients specifically before prescribing.

Drug interactions beyond nitrates

• CYP3A4 inhibitors. Tadalafil is metabolized mainly through CYP3A4. Potent inhibitors of this enzyme (certain antifungals and antiretrovirals, for example) increase tadalafil exposure, and the label addresses this with dose-limiting guidance for on-demand use. The exact magnitude of exposure increase should be confirmed against the current label text rather than repeated from a secondary summary.
• Alpha-blockers. Used for BPH; combined use with tadalafil is permitted but only after the patient is stable on alpha-blocker therapy, because of additive blood pressure lowering.
• Other antihypertensives. Generally small additional blood pressure reduction, more relevant in patients on multiple agents or prone to orthostatic hypotension.
• Alcohol. The label carries a precaution about excessive alcohol intake potentiating orthostatic hypotension when combined with tadalafil.

Counterfeit and unregulated "male enhancement" products

The FDA has repeatedly warned that dietary supplements and online products marketed as "natural" male enhancement pills have been found to contain undeclared tadalafil, sildenafil, or related analogs (FDA: tainted sexual enhancement products). This matters for two reasons distinct from the prescription-drug safety questions above: the dose in these products is uncontrolled and sometimes exceeds approved maximums, and a consumer taking such a product has no way to know they are combining an undeclared PDE5 inhibitor with a nitrate or alpha-blocker they may already be prescribed. Buying PDE5 inhibitors only from a licensed pharmacy, with a prescription, avoids this exposure entirely.

Melanoma: an unresolved observational question

An observational cohort analysis has reported a modest statistical association between PDE5 inhibitor use and incident melanoma, and later analyses have suggested that association could be confounded by shared risk factors such as UV exposure. The FDA has not added a melanoma warning to the tadalafil label. This is a genuine open research question, not a settled safety signal, and it should not be described to patients as an established risk.

What is established, what is plausible, what is not established

Established: the nitrate contraindication and its rationale; the FDA approval history and indications; the 2005 and 2007 class-wide label additions for NAION and sudden hearing loss risk language; the priapism warning; the absence of a recall or boxed warning as of the label version reviewed.

Plausible but unproven: a causal (not merely associative) link between PDE5 inhibitor use and NAION or sudden hearing loss in an individual patient; a mechanistic explanation involving cochlear or optic nerve microvascular effects.

Not established: that tadalafil independently increases myocardial infarction risk in men at low cardiovascular risk; that tadalafil causes melanoma. Both remain areas of active or unresolved observational research rather than confirmed harms.

Symptom-to-action framework: what a reported signal should make you do

This framework separates tadalafil-related symptoms by how strong the evidence is and what action that evidence actually justifies, because treating an established emergency the same as a disputed association leads to either dangerous delay or unnecessary alarm.

If a symptom in the top four rows occurs, the evidence supports treating it as urgent regardless of how rare it is reported to be, because the severity of a missed case outweighs the low absolute frequency. If a symptom is in the bottom two rows, current evidence does not support treating tadalafil as the presumed cause without other workup.

When to seek urgent or emergency care

Stop the medication and seek immediate care for: sudden vision loss in one or both eyes, sudden hearing loss or ringing in the ears, an erection lasting four hours or longer, or chest pain (do not take a nitrate without disclosing the tadalafil timing to emergency staff). Contact a prescriber for persistent or bothersome common side effects, or for questions about combining tadalafil with new prescriptions, including blood pressure medications.